Anti-insomnia pharmaceutical composition and use thereof

A composition and drug technology, applied in the field of medicine, can solve the problems of easy generation of drug resistance and poor drug efficacy in patients, and achieve the effect of reducing clinical dosage, overcoming poor curative effect and enhancing anti-insomnia effect.

Inactive Publication Date: 2018-01-16
GUILIN HAOXIN TECH SERVICE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the treatment of insomnia mainly focuses on the use of sleep aids, but the efficacy of a single sleep aid is poor, and patients are prone to drug resistance, so there is an urgent need to explore new pharmaceutical preparations for the treatment of insomnia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The preparation of embodiment 1 pharmaceutical tablet of the present invention

[0019] Prescription: 8 parts by weight of tandospirone citrate, 8 parts by weight of ramelton, 10 parts by weight of tiagabine, 80 parts by weight of lactose, 20 parts by weight of microcrystalline cellulose, 4 parts by weight of sodium carboxymethyl starch, 20 mL of ethanol, 1 part by weight of magnesium stearate;

[0020] Preparation method: Mix the prescribed amount of tandospirone citrate, ramelton, tiagabine, lactose, microcrystalline cellulose, and sodium carboxymethyl starch in a granulator, and then add ethanol to make a soft material , after drying in vacuum, sieve and granulate, then add magnesium stearate, mix evenly, and then compress into tablets.

Embodiment 2

[0021] The preparation of embodiment 2 pharmaceutical capsules of the present invention

[0022] Prescription: 5 parts by weight of tandospirone citrate, 5 parts by weight of ramelton, 5 parts by weight of tiagabine, 80 parts by weight of lactose, and 1 part by weight of magnesium stearate;

[0023] Preparation method: mix and sieve the prescribed amount of tandospirone citrate, ramelton, tiagabine, lactose, and magnesium stearate, and fill them into empty capsules.

Embodiment 3

[0024] The preparation of embodiment 3 pharmaceutical granules of the present invention

[0025] Prescription: 10 parts by weight of tandospirone citrate, 15 parts by weight of ramelton, 15 parts by weight of tiagabine, 80 parts by weight of lactose, 20 parts by weight of microcrystalline cellulose, 4 parts by weight of sodium carboxymethyl starch, Ethanol 20mL;

[0026] Preparation method: Mix the prescribed amount of tandospirone citrate, ramelton, tiagabine, lactose, microcrystalline cellulose, and sodium carboxymethyl starch in a granulator, then add ethanol to make soft Material, vacuum dried, sieved and granulated, and bagged.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an anti-insomnia pharmaceutical composition. Effective active ingredients of the anti-insomnia pharmaceutical composition comprise tandospirone citrate, Ramelteon and Tiagabine. According to the anti-insomnia pharmaceutical composition and the use thereof, the tandospirone citrate, the Ramelteon and the Tiagabine are jointly applied to the treatment of insomnia, thus, thedefects of single medication that the treatment effect is poor and patients are prone to drug dependence are overcome, a synergistic insomnia resisting enhancing effect is achieved through jointly using the three kinds of drugs, and the action of reducing toxicity can be achieved through reducing the clinical use level of one or two of the three kinds of drugs.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to an anti-insomnia medicinal composition and its application. Background technique [0002] Insomnia is the inability to fall asleep or stay asleep, resulting in a lack of sleep. Also known as sleep and sleep maintenance disorders, it is a common disease caused by various reasons such as difficulty in falling asleep, too short sleep depth or frequency, early awakening and insufficient sleep time or poor quality. Although insomnia is not a critical disease, it often affects the quality of life and hinders people's work, study and health. Long-term insomnia has brought great suffering to people and has become a public health problem more and more. [0003] Today, with the accelerated pace of society and intensified competition, the incidence of insomnia patients continues to rise. Insomnia has become a ubiquitous phenomenon and has become a hot research topic for schola...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/506A61K31/343A61K31/4535A61P25/20
Inventor 钟传新王君
Owner GUILIN HAOXIN TECH SERVICE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap